{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-035756","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.458175+00:00","generated_at":"2026-05-31T12:59:46.540594+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rocket Pharma H1 2024 net loss $131.7M; KRESLADI review ongoing, cash into 2026","bullets":["Net loss of $131.7M ($1.40/sh) for H1 2024 vs $124.0M ($1.55/sh) for H1 2023.","Cash, equivalents & investments $278.8M; runway expected into 2026.","FDA requested additional CMC info for KRESLADI (LAD-I); working to support approval.","Phase 2 pivotal enrollment ongoing for RP-A501 (Danon) and RP-L301 (PKD) initiated.","EC granted orphan medicinal product designation for RP-A601 (PKP2-ACM); Phase 1 enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-035756","json":"https://secwatch.observer/filing/0001140361-24-035756.json","markdown":"https://secwatch.observer/filing/0001140361-24-035756.md","text":"https://secwatch.observer/filing/0001140361-24-035756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124035756/0001140361-24-035756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124035756/ef20033571_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:59:46.540594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}